Independent Psychedelic Evidence Assessment Working Group (IPEA-WG)

The Independent Psychedelic Evidence Assessment Working Group (IPEA-WG) is a multidisciplinary working group focused on how evidence for psychedelic therapies should be evaluated. Its public materials indicate an international scope, with chairs and members from Europe, North America, and Brazil, and it appears to engage scientists, philosophers, clinicians, and regulatory experts rather than a single patient population. The group's core activity is to assess evidence-evaluation frameworks and develop expert recommendations relevant to regulators and policy design.

IPEA-WG positions itself in the psychedelic medicine policy space by examining methodological and regulatory questions such as causality, trial design, conflicts of interest, and the limits of current evidence standards. Its site highlights talks, papers, and member expertise, and a public funder page says Norrsken Mind is supporting the group to develop rigorous, multidisciplinary standards for evaluating psychedelic evidence. Practical collaboration could include research consultation, regulatory science input, evidence-framework discussions, and policy briefings for clinicians, funders, and patient communities interested in access grounded in stronger evidence.